{
    "Clinical Trial ID": "NCT00209092",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A:Sequential Therapy",
        "  Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).",
        "INTERVENTION 2: ",
        "  Arm B:Concurrent Therapy",
        "  Docetaxel will be given at 50mg/m^2 intravenously Day 1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically or cytologically confirmed breast carcinoma.",
        "  Early stage breast cancer (stage 1, 2, 3).",
        "  No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.",
        "  18 years of age or older.",
        "  Final eligibility for a clinical trial is determined by the health professionals conducting the trial.",
        "Exclusion Criteria:",
        "  Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.",
        "  Major surgery within 28 days of study entry.",
        "  Evidence of central nervous system (CNS) metastases.",
        "  Final eligibility for a clinical trial is determined by the health professionals conducting the trial."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B (Docetaxel + Capecitabine for 8 Cycles) in Patients With Early Stage Breast Cancer.",
        "  Pathologic complete response (pCR): Absence of invasive breast cancer in the breast.",
        "  Overall Clinical Response=Complete response(CR-complete disappearance of all measurable malignant disease)+partial response(PR-reduction by at least 30%)",
        "  Stable disease (SD): No decrease or <25% increase in the sum of the products of the longest perpendicular diameters of all measurable lesions.",
        "  Progressive disease (PD): A 20% or greater increase in a single lesion, OR reappearance of any lesion which has disappeared, OR clear worsening of any evaluable disease OR appearance of any new lesion/site.",
        "Time frame: 1 year",
        "Results 1: ",
        "  Arm/Group Title: Arm A:Sequential Therapy",
        "  Arm/Group Description: Docetaxel will be given at 100mg/m^2 intravenously Day1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth D1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).",
        "  Overall Number of Participants Analyzed: 25",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Pathologic Complete Response-Overall population: 2",
        "  Overall Clinical Response: 15",
        "  Stable disease: 3",
        "  Progressive Disease: 7",
        "Results 2: ",
        "  Arm/Group Title: Arm B:Concurrent Therapy",
        "  Arm/Group Description: Docetaxel will be given at 50mg/m^2 intravenously Day 1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).",
        "  Overall Number of Participants Analyzed: 26",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Pathologic Complete Response-Overall population: 3",
        "  Overall Clinical Response: 23",
        "  Stable disease: 1",
        "  Progressive Disease: 2"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/25 (24.00%)",
        "  Neutropenia *3/25 (12.00%)",
        "  Anemia *0/25 (0.00%)",
        "  Febrile Neutropenia *0/25 (0.00%)",
        "  Chest Pain *0/25 (0.00%)",
        "  Diarrhea *1/25 (4.00%)",
        "  Fatigue *1/25 (4.00%)",
        "  Liver Tests *0/25 (0.00%)",
        "  Neuropathy *0/25 (0.00%)",
        "  Syncope *0/25 (0.00%)",
        "  Hand and Foot Syndrome *1/25 (4.00%)",
        "Adverse Events 2:",
        "  Total: 11/26 (42.31%)",
        "  Neutropenia *3/26 (11.54%)",
        "  Anemia *1/26 (3.85%)",
        "  Febrile Neutropenia *1/26 (3.85%)",
        "  Chest Pain *1/26 (3.85%)",
        "  Diarrhea *1/26 (3.85%)",
        "  Fatigue *0/26 (0.00%)",
        "  Liver Tests *1/26 (3.85%)",
        "  Neuropathy *1/26 (3.85%)",
        "  Syncope *1/26 (3.85%)",
        "  Hand and Foot Syndrome *1/26 (3.85%)"
    ]
}